Prognostic role of low muscle mass and strength in palliative care patients with incurable cancer: a retrospective study

Sarcopenic obesity by the ESPEN/EASO criteria for predicting mortality in advanced non-small cell lung cancer

BACKGROUND

The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) recently released the first international consensus on the diagnostic criteria for sarcopenic obesity (SO), which recommended skeletal muscle mass adjusted for body weight (SMM/W) to determine low muscle mass. SMM adjusted for body mass index (SMM/BMI) appeared to be better associated with physical performance than SMM/W. Thus, we modified the ESPEN/EASO criteria by using SMM/BMI. We aimed (1) to evaluate the agreement of the ESPEN/EASO-defined SO (SO_ESPEN) and the modified ESPEN/EASO-defined SO (SO_ESPEN-M) with other commonly used SO definitions, and (2) to compare different SO definitions for predicting mortality in a prospective cohort with advanced non-small cell lung cancer (NSCLC).

METHODS

This prospective study included patients with advanced NSCLC. We defined SO according to five different diagnostic criteria: SO_ESPEN, SO_ESPEN-M, Asian Working Group for Sarcopenia (AWGS)-determined sarcopenia with BMI-determined obesity (SO_AWGS), computed tomography-derived sarcopenia with BMI-determined obesity (SO_CT), and fat mass to fat-free mass ratio >0.8 (SO_FM). The outcome was all-cause mortality.

RESULTS

Of the 639 participants (mean age 58.6 years, 229 women) we studied, 488 (76.4%) died during the median follow-up period of 25 months. SMM/BMI was significantly lower in the death group than in the survivor group (men: p = 0.001, women: p < 0.001), but SMM/W was not. Only 3 (0.47%) participants met all five SO diagnostic criteria. SO_ESPEN showed an excellent agreement with SO_ESPEN-M (Cohen's kappa = 0.896), a moderate agreement with SO_AWGS (Cohen's kappa = 0.415), but poor agreements with SO_CT and SO_FM (Cohen's kappa = 0.078 and 0.092, respectively). After full adjustment for potential confounders, SO_ESPEN (HR 1.54, 95% CI 1.26-1.89), SO_ESPEN-M (HR 1.56, 95% CI 1.26-1.92), and SO_AWGS (HR 1.43, 95% CI 1.14-1.78) were significantly associated with mortality. However, SO_CT (HR 1.17, 95% CI 0.87-1.58) and SO_FM (HR 1.15, 95% CI 0.90-1.46) showed no significant association with mortality.

CONCLUSIONS

SO_ESPEN showed an excellent agreement with SO_ESPEN-M, a moderate agreement with SO_AWGS, but poor agreements with SO_CT and SO_FM. SO_ESPEN, SO_ESPEN-M, and SO_AWGS were independent prognostic factors for mortality in our study population, but SO_CT and SO_FM were not. Although SMM/BMI was better associated with survival than SMM/W, SO_ESPEN-M did not show an advantage in predicting survival over SO_ESPEN.

Cachexia staging score predicts survival in patients with cancer who receive palliative care

OBJECTIVE

The aim of this study was to validate the cachexia staging score (CSS), a multidimensional, item-based diagnostic method of cachexia severity, for patients with advanced cancer receiving palliative care.

METHODS

Eligible patients were those with cancer who received palliative care during hospitalization between May 2019 and April 2020. All data were collected retrospectively from medical records. Cachexia was graded into four levels according to the CSS. Kaplan-Meier curves were constructed with or without death as the outcome, comparing prognoses among different levels of cachexia with Bonferroni correction. Cox proportional hazards regression analysis was performed to identify factors affecting mortality.

RESULTS

The mean age of the 196 patients was 65.8 ± 14 y. Men made up 42% of the study population. Lower body mass index, increased rate of weight loss, increased strength, assistance walking, rising from a chair, climbing stairs, and falls (SARC-F) points, decline in activities of daily living, appetite loss, and abnormal blood biomarkers were significantly more common with increasing severity of cachexia, and survival was shorter (P < 0.001). The hazard ratio (HR) increased with worsening severity of cachexia according to CSS classification (precachexia: HR, 2.78; 95% confidence interval [CI], 0.62-12.46, P = 0.182; cachexia: HR, 4.77; 95% CI, 1.09-20.80; P = 0.038; and refractory cachexia: HR, 11.00; 95% CI, 2.37-51.07; P = 0.002).

CONCLUSIONS

The CSS predicted life expectancy in a population of patients receiving palliative care and had excellent prognostic discriminative power to classify patients at different stages of cachexia.

High SARC-F score predicts poor survival of patients with cancer receiving palliative care

PURPOSE

A high score determined by SARC-F, a simple screening questionnaire for sarcopenia, has been reportedly associated with worse medical outcomes. However, information regarding whether high SARC-F scores are associated with a poor prognosis in patients with advanced cancer remains limited. We clarified whether a SARC-F score ≥ 4 predicts poor prognosis in patients with cancer receiving palliative care.

METHODS

We conducted a retrospective cohort study of patients with cancer who received palliative care at a university hospital between May 2019 and April 2020. Patient characteristics including age, sex, height, weight, cancer type, serum albumin level, C-reactive protein level, presence of edema, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS), SARC-F score, history of anticancer therapy, and clinical outcomes were collected from electronic medical records.

RESULTS

Of 304 patients, 188 had a SARC-F score < 4, and 116 patients had a SARC-F score ≥ 4. The overall survival of patients with a SARC-F score ≥ 4 was 40 days (95% CI 29-47), which was significantly worse than 121 days (95% CI 95-156) for patients with a SARC-F score < 4 (p < 0.001). SARC-F score ≥ 4 (hazard ratio: HR 1.56), edema (HR 1.94), head and neck cancer (HR 0.51), C-reactive protein (HR 1.05), ECOG-PS ≥ 3 (HR 1.47), and radiotherapy (HR 0.52) were associated with overall survival. The ability to climb stairs was a SARC-F sub-item significantly associated with mortality (HR 1.59).

CONCLUSION

The SARC-F questionnaire is a useful predictor of prognosis for patients with cancer receiving palliative care because a SARC-F ≥ 4 score predicts worse overall survival.